Viking Therap

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Viking Therap(VKTX.US) Viking Therapeutics Launches Phase 1 Trial for New Weight-Loss Drug VK3019

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ 𝐕𝐢𝐤𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 initiated a 𝐏𝐡𝐚𝐬𝐞 𝟏 trial of weight-loss candidate VK3019.

➤ VK3019 is a 𝐝𝐮𝐚𝐥 𝐚𝐦𝐲𝐥𝐢𝐧 and 𝐜𝐚𝐥𝐜𝐢𝐭𝐨𝐧𝐢𝐧 receptor agonist (DACRA).

➤ Trial follows 𝐅𝐃𝐀 clearance of VK3019's Investigational New Drug application.

➤ Study will evaluate 𝐬𝐚𝐟𝐞𝐭𝐲, 𝐭𝐨𝐥𝐞𝐫𝐚𝐛𝐢𝐥𝐢𝐭𝐲, and pharmacokinetics in adults with BMI ≥ 30.

➤ Exploratory assessments include changes in 𝐛𝐨𝐝𝐲 𝐰𝐞𝐢𝐠𝐡𝐭 after a single dose.

➤ Preclinical data showed up to 𝟖% 𝐛𝐨𝐝𝐲-𝐰𝐞𝐢𝐠𝐡𝐭 reduction within 72 hours in animal studies.

➤ Viking is also conducting 𝐏𝐡𝐚𝐬𝐞 𝟑 VANQUISH trials for obesity drug VK2735.

➤ Company plans to launch a 𝐏𝐡𝐚𝐬𝐞 𝟑 trial of oral VK2735 later in 2026.

👉 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:

➤ VK3019 expands Viking's pipeline in the rapidly growing 𝐨𝐛𝐞𝐬𝐢𝐭𝐲 treatment market.

➤ DACRA therapies could complement 𝐆𝐋𝐏-𝟏 and GLP-1/GIP weight-loss medicines.

➤ Success could provide additional 𝐥𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐰𝐞𝐢𝐠𝐡𝐭-𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 options for patients.

👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:

➤ "The initiation of VK3019's Phase 1 study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧, Ph.D., Chief Executive Officer of Viking Therapeutics.

➤ "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧.

➤ "Broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss." — 𝐁𝐫𝐢𝐚𝐧 𝐋𝐢𝐚𝐧.

$Viking Therap(VKTX.US) | Truist Securities 𝐫𝐞𝐢𝐭𝐞𝐫𝐚𝐭𝐞𝐬 𝐁𝐮𝐲 on 𝐕𝐢𝐤𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, 𝐫𝐚𝐢𝐬𝐞𝐬 𝐏𝐓 𝐭𝐨 $𝟖𝟑 𝐟𝐫𝐨𝐦 $𝟕𝟓

Analyst sees VKTX as a differentiated obesity player, citing fast efficacy, flexible formulations for adherence, and a diversified metabolics pipeline.

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Viking Therap(VKTX.US) Viking Therapeutics Reports Phase 2 Oral VK2735 Obesity Data

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ Oral 𝐕𝐊𝟐𝟕𝟑𝟓 achieved up to 𝟏𝟐.𝟐% weight loss in 𝟏𝟑 weeks.

➤ Placebo group recorded 𝟏.𝟑% average weight reduction.

➤ Trial enrolled 𝟐𝟖𝟎 adults with obesity or overweight conditions.

➤ Weight loss began by 𝐰𝐞𝐞𝐤 𝟏 and continued without plateauing.

➤ Up to 𝟗𝟕% of participants achieved at least 𝟓% weight loss.

➤ Treatment targets both 𝐆𝐋𝐏-𝟏 and 𝐆𝐈𝐏 receptors.

➤ Viking plans to launch 𝐏𝐡𝐚𝐬𝐞 𝟑 trials for oral VK2735 this year.

Top earnings plays I am watching from today's reports

$Eli Lilly(LLY.US) $Viking Therap(VKTX.US) $Textron(TXT.US) $GE Vernova(GEV.US) $Teradyne(TER.US) $Intercontinental Exchange(ICE.US)

$Viking Therap(VKTX.US) | 𝐕𝐢𝐤𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬: Raymond James reiterates 𝐒𝐭𝐫𝐨𝐧𝐠 𝐁𝐮𝐲, maintains 𝐏𝐓 𝐚𝐭 $𝟏𝟏𝟖

Analyst sees GLP-1/GIP data readthrough as neutral-to-positive, with no meaningful LBM disadvantage and stronger weight loss profile supporting VKTX outlook.

Source: Hardik Shah